Evidence map›Paper›PMID 38493435›Full record

ArticleJournal of bone and mineral metabolism2024

Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan.

Hisashi Matsushima, Tetsuya Taguchi, Sho Kodama, Naoki Okubo, Kengo Saito, Katarzyna Jabłońska, Seiji Fukumoto, Toshio Matsumoto

Open access · hybridAbstract read
In one paragraph

Article in Journal of bone and mineral metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Observational
  3. Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.International journal of urology : official journal of the Japanese Urological Association · 2025
    Observational
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hisashi MatsushimaDepartment of Urology, Tokyo Metropolitan Police Hospital, 4-22-1 Nakano, Nakano-ku, Tokyo, 164-8541, Japan. hmatsu53@me.com.ORCID http://orcid.org/0000-0002-2567-8008
Tetsuya TaguchiDivision of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Sho KodamaPrimary Medical Science Department, Medical Affairs Division, Japan Business Unit, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Naoki OkuboData Intelligence Department, Global DX, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Kengo SaitoPrimary Medical Science Department, Medical Affairs Division, Japan Business Unit, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
Katarzyna JabłońskaPutnam PHMR, Kraków, Poland.
Seiji FukumotoTokushima University, Tokushima, Japan.
Toshio MatsumotoTokushima University, Tokushima, Japan.
Daiichi-Sankyo (Japan) · JPTokushima University · JPKyoto Prefectural University of Medicine · JPTokyo Metropolitan Police Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAndrogen deprivation therapy (ADT) is widely used for the treatment of prostate cancer. ADT is associated with reduced bone density leading to an increased risk of osteoporotic fracture. The objective of this retrospective cohort study was to quantify fracture risk in men treated with ADT for prostate cancer in real-world practice in Japan. MATERIALS AND

methodsData were extracted from the Japanese Medical Data Vision (MDV) database. Men initiating ADT for treatment of prostate cancer between April 2010 and March 2021 were identified and matched to a cohort of prostate cancer patients not taking ADT using a propensity score. Fracture rates were estimated by a cumulative incidence function and compared between cohorts using a Cox cause-specific hazard model. Information was extracted on demographics, comorbidities and bone densitometry.

results30,561 men with PC starting ADT were matched to 30,561 men with prostate cancer not treated with ADT. Following ADT initiation, <5% of men underwent bone densitometry. Prescription of ADT was associated with an increased fracture risk compared to not taking ADT (adjusted hazard ratio: 1.63 [95% CI 1.52-1.75]).

conclusionADT is associated with a 1.6-fold increase in the risk of osteoporotic fracture in men with prostate cancer. Densitometry in this population is infrequent and monitoring urgently needs to be improved in order to implement effective fracture prevention.

Indexed as

InsuranceOsteoporotic FracturesProstatic NeoplasmsAndrogen AntagonistsAndrogensHumansJapanMaleRetrospective StudiesAndrogen AntagonistsAndrogensAndrogen-deprivation therapyEpidemiologyFracture riskJapanOsteoporosisProstate cancer

Identifiers

PMID38493435
PMCPMC10982088
OpenAlexW4392895327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.